Abstract:After acute ischemic stroke, ANXA6 transfers from cytoplasm to cell membrane, exerting a protective role. ANXA6 overexpression can increase expression levels of MBP, TRKB, neuroligin, and synaptophysin, alleviating neurological deficits. Aims Alleviating neurological dysfunction caused by acute ischemic stroke (AIS) remains intractable. Given Annexin A6 (ANXA6)'s potential in promoting axon branching and repairing cell membranes, the study aimed to explore ANXA6's potential in alleviating AIS‐induced neurological dysfunction. Methods A mouse middle cerebral artery occlusion model was established. Brain and plasma ANXA6 levels were detected at different timepoints post ischemia/reperfusion (I/R). We overexpressed and down‐regulated brain ANXA6 and evaluated infarction volume, neurological function, and synaptic plasticity‐related proteins post I/R. Plasma ANXA6 levels were measured in patients with AIS and healthy controls, investigating ANXA6 expression's clinical significance. Results Brain ANXA6 levels initially decreased, gradually returning to normal post I/R; plasma ANXA6 levels showed an opposite trend. ANXA6 overexpression significantly decreased the modified neurological severity score (p = 0.0109) 1 day post I/R and the infarction area at 1 day (p = 0.0008) and 7 day (p = 0.0013) post I/R, and vice versa. ANXA6 positively influenced synaptic plasticity, upregulating synaptophysin (p = 0.006), myelin basic protein (p = 0.010), neuroligin (p = 0.078), and tropomyosin‐related kinase B (p = 0.150). Plasma ANXA6 levels were higher in patients with AIS (1.969 [1.228–3.086]) compared to healthy controls (1.249 [0.757–2.226]) (p

Annexin A6 mitigates neurological deficit in ischemia/reperfusion injury by promoting synaptic plasticity